Trulieve Cannabis Corp. revenue
Trulieve Cannabis Corp.'s revenue was $1.18bn in fiscal 2025, down 0.4% on the year before. Since fiscal 2019 ($253m) it has grown at a compound 29.3% a year. Over the last twelve months it was $1.14bn.
Revenue history
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 253 | 522 | 932 | 1,218 | 1,129 | 1,186 | 1,181 | 1,139 |
| Growth on the year before | — | +106.3% | +78.7% | +30.7% | −7.3% | +5.1% | −0.4% | — |
| Gross profit | 192 | 386 | 567 | 689 | 589 | 716 | 711 | 677 |
| Gross margin | 75.9% | 74.1% | 60.8% | 56.6% | 52.1% | 60.3% | 60.2% | 59.5% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Retail | $1.1B | 94.0% | ▼ 1.6% |
| Wholesale and Other | $70.7M | 6.0% | ▲ 22.8% |
From Trulieve Cannabis Corp.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Trulieve Cannabis Corp. | $1.14bn | -3.9% | -0.6% |
| Prestige Consumer Healthcare Inc. | $1.10bn | -1.4% | -0.7% |
| ANI Pharmaceuticals Inc | $978m | 30.9% | 34.6% |
| Harmony Biosciences Holdings, Inc. | $960m | 24.3% | 24.4% |
| Indivior Pharmaceuticals, Inc. | $1.37bn | 16.3% | — |
| Axsome Therapeutics, Inc. | $865m | 54.2% | 57.0% |
Compare with peers
- Prestige Consumer Healthcare Inc. revenue
- ANI Pharmaceuticals Inc revenue
- Harmony Biosciences Holdings, Inc. revenue
- Indivior Pharmaceuticals, Inc. revenue
- Axsome Therapeutics, Inc. revenue
Head to head: PBH vs TRLVANIP vs TRLVHRMY vs TRLVINDV vs TRLV
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies